

Robert Elashoff

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12120981/publications.pdf>

Version: 2024-02-01

69
papers

12,141
citations

57758

44
h-index

98798

67
g-index

69
all docs

69
docs citations

69
times ranked

9652
citing authors

#	ARTICLE	IF	CITATIONS
1	Preoperative Ultrasound Assessment of Regional Lymph Nodes in Melanoma Patients Does not Provide Reliable Nodal Staging. <i>Annals of Surgery</i> , 2021, 273, 814-820.	4.2	16
2	E-Cigarette Use and Subclinical Cardiac Effects. <i>Circulation Research</i> , 2020, 127, 1566-1567.	4.5	5
3	Bevacizumab at first recurrence after standard radio-chemotherapy is associated with improved overall survival in glioblastoma patients with large tumor burden. <i>Neuro-Oncology Practice</i> , 2019, 6, 103-111.	1.6	3
4	Racial-ethnic differences in chronic kidney disease-mineral bone disorder in youth on dialysis. <i>Pediatric Nephrology</i> , 2019, 34, 107-115.	1.7	7
5	Estriol-mediated neuroprotection in multiple sclerosis localized by voxel-based morphometry. <i>Brain and Behavior</i> , 2018, 8, e01086.	2.2	22
6	Electronic Cigarettes Impair Human Coronary Endothelial Function. <i>FASEB Journal</i> , 2018, 32, 579.4.	0.5	0
7	Human <i>TERT</i> promoter mutation enables survival advantage from <i>MGMT</i> promoter methylation in <i>IDH1</i> wild-type primary glioblastoma treated by standard chemoradiotherapy. <i>Neuro-Oncology</i> , 2017, 19, now189.	1.2	65
8	A phase 3 randomized placebo-controlled trial of tadalafil for Duchenne muscular dystrophy. <i>Neurology</i> , 2017, 89, 1811-1820.	1.1	58
9	Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases. <i>Annals of Surgical Oncology</i> , 2017, 24, 3991-4000.	1.5	102
10	Derivation and Validation of a Geriatric-Sensitive Perioperative Cardiac Risk Index. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	27
11	Impact of Time Between Diagnosis and SLNB on Outcomes in Cutaneous Melanoma. <i>Journal of the American College of Surgeons</i> , 2017, 225, 302-311.	0.5	20
12	Disability-Specific Atlases of Gray Matter Loss in Relapsing-Remitting Multiple Sclerosis. <i>JAMA Neurology</i> , 2016, 73, 944.	9.0	24
13	Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 374-381.	0.9	76
14	Transitions to different patterns of interstitial lung disease in scleroderma with and without treatment. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1367-1371.	0.9	35
15	Longitudinal data analysis with non-ignorable missing data. <i>Statistical Methods in Medical Research</i> , 2016, 25, 205-220.	1.5	19
16	Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial. <i>Lancet Neurology</i> , The, 2016, 15, 35-46.	10.2	158
17	Sodium nitrate alleviates functional muscle ischaemia in patients with Becker muscular dystrophy. <i>Journal of Physiology</i> , 2015, 593, 5183-5200.	2.9	26
18	Final Trial Report of Sentinel-Node Biopsy versus Nodal Observation in Melanoma. <i>New England Journal of Medicine</i> , 2014, 370, 599-609.	27.0	1,203

#	ARTICLE	IF	CITATIONS
19	Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy. <i>Neuro-Oncology</i> , 2014, 16, 815-822.	1.2	49
20	Lack of FGF23 Response to Acute Changes in Serum Calcium and PTH in Humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E1951-E1956.	3.6	14
21	Online Self-Report Data for Duchenne Muscular Dystrophy Confirms Natural History and Can Be Used to Assess for Therapeutic Benefits. <i>PLOS Currents</i> , 2014, 6, .	1.4	25
22	A Critical Analysis of the Clinical Use of Incretin-Based Therapies. <i>Diabetes Care</i> , 2013, 36, 2118-2125.	8.6	264
23	Interaction between <i>Pseudomonas</i> and CXC Chemokines Increases Risk of Bronchiolitis Obliterans Syndrome and Death in Lung Transplantation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 187, 518-526.	5.6	84
24	The Skeletal Consequences of Growth Hormone Therapy in Dialyzed Children. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 824-832.	4.5	28
25	Early Skeletal and Biochemical Alterations in Pediatric Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 146-152.	4.5	144
26	Assessment of Prognostic Circulating Tumor Cells in a Phase III Trial of Adjuvant Immunotherapy After Complete Resection of Stage IV Melanoma. <i>Annals of Surgery</i> , 2012, 255, 357-362.	4.2	83
27	Metastasectomy for Distant Metastatic Melanoma: Analysis of Data from the First Multicenter Selective Lymphadenectomy Trial (MSLT-I). <i>Annals of Surgical Oncology</i> , 2012, 19, 2547-2555.	1.5	155
28	Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1-Based Therapies. <i>Gastroenterology</i> , 2011, 141, 150-156.	1.3	734
29	Adverse Events during the Scleroderma Lung Study. <i>American Journal of Medicine</i> , 2011, 124, 459-467.	1.5	30
30	Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. <i>Kidney International</i> , 2011, 79, 112-119.	5.2	148
31	Quantitative texture-based assessment of one-year changes in fibrotic reticular patterns on HRCT in scleroderma lung disease treated with oral cyclophosphamide. <i>European Radiology</i> , 2011, 21, 2455-2465.	4.5	99
32	Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: Analysis of the Scleroderma Lung Study Placebo Group. <i>Arthritis and Rheumatism</i> , 2011, 63, 3078-3085.	6.7	107
33	Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme. <i>Journal of Clinical Oncology</i> , 2011, 29, 142-148.	1.6	418
34	Course of dermal ulcers and musculoskeletal involvement in systemic sclerosis patients in the scleroderma lung study. <i>Arthritis Care and Research</i> , 2010, 62, 1772-1778.	3.4	29
35	Protection against Bronchiolitis Obliterans Syndrome Is Associated with Allograft CCR7+CD45RA ^{hi} T Regulatory Cells. <i>PLoS ONE</i> , 2010, 5, e11354.	2.5	32
36	The Calcemic Response to Continuous Parathyroid Hormone (PTH)(1-34) Infusion in End-Stage Kidney Disease Varies According to Bone Turnover: A Potential Role for PTH(7-84). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 2772-2780.	3.6	67

#	ARTICLE	IF	CITATIONS
37	The Impact on Morbidity and Length of Stay of Early Versus Delayed Complete Lymphadenectomy in Melanoma: Results of the Multicenter Selective Lymphadenectomy Trial (I). <i>Annals of Surgical Oncology</i> , 2010, 17, 3324-3329.	1.5	177
38	International Randomized Clinical Trial, Stroke Inpatient Rehabilitation With Reinforcement of Walking Speed (SIRROWS), Improves Outcomes. <i>Neurorehabilitation and Neural Repair</i> , 2010, 24, 235-242.	2.9	129
39	Systemic sclerosis-associated interstitial lung disease-proposed recommendations for future randomized clinical trials. <i>Clinical and Experimental Rheumatology</i> , 2010, 28, S55-62.	0.8	32
40	Surfactant Protein D and KL-6 as Serum Biomarkers of Interstitial Lung Disease in Patients with Scleroderma. <i>Journal of Rheumatology</i> , 2009, 36, 773-780.	2.0	153
41	Treatment of Scleroderma-Interstitial Lung Disease With Cyclophosphamide Is Associated With Less Progressive Fibrosis on Serial Thoracic High-Resolution CT Scan Than Placebo. <i>Chest</i> , 2009, 136, 1333-1340.	0.8	127
42	Minimally important differences in the Mahler's Transition Dyspnoea Index in a large randomized controlled trial-results from the Scleroderma Lung Study. <i>Rheumatology</i> , 2009, 48, 1537-1540.	1.9	46
43	Classification of Parenchymal Abnormality in Scleroderma Lung Using a Novel Approach to Denoise Images Collected via a Multicenter Study. <i>Academic Radiology</i> , 2008, 15, 1004-1016.	2.5	61
44	Sentinel Node Biopsy: Facts to Clear the Alleged Clouds. <i>Archives of Dermatology</i> , 2008, 144, 685.	1.4	11
45	Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1641-1647.	0.9	74
46	Effects of 1-Year Treatment with Cyclophosphamide on Outcomes at 2 Years in Scleroderma Lung Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007, 176, 1026-1034.	5.6	411
47	Validity of the Walking Scale for Spinal Cord Injury and Other Domains of Function in a Multicenter Clinical Trial. <i>Neurorehabilitation and Neural Repair</i> , 2007, 21, 539-550.	2.9	98
48	Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: Results from the scleroderma lung study. <i>Arthritis and Rheumatism</i> , 2007, 56, 1676-1684.	6.7	93
49	Reliability and Validity of Bilateral Thigh and Foot Accelerometry Measures of Walking in Healthy and Hemiparetic Subjects. <i>Neurorehabilitation and Neural Repair</i> , 2006, 20, 297-305.	2.9	104
50	Cyclophosphamide versus Placebo in Scleroderma Lung Disease. <i>New England Journal of Medicine</i> , 2006, 354, 2655-2666.	27.0	1,421
51	Sentinel-Node Biopsy or Nodal Observation in Melanoma. <i>New England Journal of Medicine</i> , 2006, 355, 1307-1317.	27.0	1,679
52	Sentinel Node Biopsy for Early-Stage Melanoma. <i>Annals of Surgery</i> , 2005, 242, 302-313.	4.2	632
53	Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: Results from the scleroderma lung study. <i>Arthritis and Rheumatism</i> , 2005, 52, 592-600.	6.7	120
54	Prognostic Significance of Molecular Upstaging of Paraffin-Embedded Sentinel Lymph Nodes in Melanoma Patients. <i>Journal of Clinical Oncology</i> , 2004, 22, 2671-2680.	1.6	137

#	ARTICLE	IF	CITATIONS
55	Prediction of metastatic melanoma in nonsentinel nodes and clinical outcome based on the primary melanoma and the sentinel node. <i>Modern Pathology</i> , 2004, 17, 747-755.	5.5	169
56	Reply to the letter from J. I. Minguela and R. Ruiz-de-Gauna. <i>Pediatric Nephrology</i> , 2004, 19, 947.	1.7	0
57	Body weight loss with phentermine alone versus phentermine and fenfluramine with very-low-calorie diet in an outpatient obesity management program: a retrospective study. <i>Current Therapeutic Research</i> , 2003, 64, 447-460.	1.2	14
58	Methods for a Randomized Trial of Weight-Supported Treadmill Training Versus Conventional Training for Walking During Inpatient Rehabilitation after Incomplete Traumatic Spinal Cord Injury. <i>Neurorehabilitation and Neural Repair</i> , 2003, 17, 153-167.	2.9	143
59	Lymphatic Mapping and Sentinel Lymphadenectomy for Early-Stage Melanoma. <i>Annals of Surgery</i> , 2003, 238, 538-550.	4.2	249
60	Liquid Meal Replacements and Glycemic Control in Obese Type 2 Diabetes Patients. <i>Obesity</i> , 2001, 9, 341S-347S.	4.0	69
61	Increased Incidence of Second Primary Melanoma in Patients With a Previous Cutaneous Melanoma. <i>Annals of Surgical Oncology</i> , 1999, 6, 705-711.	1.5	100
62	Prognostic Significance of Occult Metastases Detected by Sentinel Lymphadenectomy and Reverse Transcriptase-PCR Polymerase Chain Reaction in Early-Stage Melanoma Patients. <i>Journal of Clinical Oncology</i> , 1999, 17, 3238-3244.	1.6	260
63	Validation of the Accuracy of Intraoperative Lymphatic Mapping and Sentinel Lymphadenectomy for Early-Stage Melanoma. <i>Annals of Surgery</i> , 1999, 230, 453.	4.2	694
64	Polyvalent Melanoma Vaccine Improves Survival of Patients with Metastatic Melanoma. <i>Annals of the New York Academy of Sciences</i> , 1993, 690, 120-134.	3.8	61
65	Prolongation of Survival in Metastatic Melanoma After Active Specific Immunotherapy With a New Polyvalent Melanoma Vaccine. <i>Annals of Surgery</i> , 1992, 216, 463-482.	4.2	360
66	Adjuvant dietary fat intake reduction in postmenopausal breast cancer patient management. <i>Breast Cancer Research and Treatment</i> , 1991, 20, 73-84.	2.5	91
67	Unpublished data summaries and the design and conduct of clinical trials. <i>Contemporary Clinical Trials</i> , 1989, 10, 368-377.	1.9	8
68	Mitoxantrone use in breast cancer patients with elevated bilirubin. <i>Breast Cancer Research and Treatment</i> , 1989, 14, 267-274.	2.5	5
69	A breast cancer nutrition adjuvant study (NAS): Protocol design and initial patient adherence. <i>Breast Cancer Research and Treatment</i> , 1987, 10, 21-29.	2.5	37